In Brief: Label Changes for Testosterone Products

The FDA has required changes in the labels of all testosterone products to reflect new data on their cardiovascular effects. The updated labels will no longer include a boxed warning about an increased risk of adverse cardiovascular outcomes, but will contain a new warning about an increase in blood pressure.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-04-03
DOI: https://doi.org/10.58347/tml.2025.1726d
Primary Topic: Hormonal and reproductive studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

In Brief: Label Changes for Testosterone Products

Apr 3, 2025

1 links

The medical letter on drugs and therapeutics/The medical letter

Hormonal and reproductive studies

article

In Brief: Label Changes for Testosterone Products

April 3, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1726)

Good health and well-being

Openalex Percentile: Top 91%

Hormonal and reproductive studies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: Label Changes for Testosterone Products · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS